MorphoSys to Present Clinical Trial Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2016
MorphoSys AG / MorphoSys to Present Clinical Trial Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2016 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Lesen Sie auch
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced the publication of three abstracts which were accepted for the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 3 to June 7 in Chicago, Illinois, USA. The abstracts include updated clinical data on the Company's proprietary drug candidate MOR202 from a phase 1/2a study in patients with multiple myeloma as well as a patient subgroup analysis from the phase 2 study of MOR208 in non-Hodgkin's lymphoma (NHL). The MOR202 abstract has also been selected by the conference organizers for discussion in a separate session. In addition, partners of MorphoSys will present data on several HuCAL antibodies that are currently in clinical development.
"We are delighted to publish a new package of clinical data at the preeminent conference on clinical oncology. The data set provides additional insight into the progress of our lead cancer compounds MOR208 and MOR202," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "For MOR202, we are in particular looking forward to presenting additional efficacy data from the dose escalation Phase 1/2a study in multiple myeloma in combination with lenalidomide and with pomalidomide."
List of abstracts relating to MorphoSys's proprietary programs
Abstract #8012
MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple
myeloma: Data from clinically relevant cohorts from a phase 1/2a study.
The poster presentation will include safety results and, in particular, efficacy from additional patient cohorts receiving the anti CD38 antibody MOR202 alone and in combination with pomalidomide
or lenalidomide from the ongoing trial. The poster presentation will take place on Monday, June 6, 8:00 am - 11:30 am CDT, as part of the Hematologic Malignancies - Plasma Cell Dyscrasia track. The
findings will be discussed at the poster discussion session on Monday, June 6, 2016, 3:00 PM - 4:15 PM CDT, at E354b.